Alivus Life Sciences Ltd
Alivus Life Sciences Ltd
HealthcareKey Fundamentals
SmallcapPharmaceuticalsHealthcareInsights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alivus Life Sciences Ltd insights
45 extracted metrics + investor summaries across FY18–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
2- Company is almost debt free.
- Company has been maintaining a healthy dividend payout of 27.4%
Weaknesses
2- The company has delivered a poor sales growth of 6.24% over past five years.
- Company has high debtors of 153 days.
Growth Rate
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 5d agoAlivus Life Sciences Ltd is a nearly debt-free healthcare company with a market cap of ₹16,673 Cr, trading at a P/E of 27.7x and P/B of 5.02x. The company has delivered strong profit growth of 25% TTM but sales growth remains subdued at 6% over five years, with high debtor days of 153 indicating working capital challenges.
- Company is almost debt-free, providing financial flexibility and low interest burden in a rising rate environment
- Consistent ROE of 19-21% over 3-5 years demonstrates efficient capital allocation and strong profitability
- TTM profit growth of 25% significantly outpaces sales growth, indicating margin expansion and operating leverage
- Healthy dividend payout of 27.4% with a dividend yield of 0.37%, reflecting shareholder-friendly capital return policy
- Stock CAGR of 42% over 1 year and 28% over 3 years shows sustained re-rating by the market
- 5-year compounded profit growth of 11% exceeds 5-year sales growth of 6%, suggesting improving cost efficiencies over time
- Healthcare sector positioning provides defensive characteristics and long-term structural demand tailwinds in India
- Poor sales growth of only 6% CAGR over 5 years signals limited top-line momentum for a mid-cap healthcare company
- High debtor days of 153 indicate significant working capital stress and potential collection risk from customers
- P/E of 27.7x appears elevated relative to the modest 6% sales growth, suggesting limited margin of safety
- P/B of 5.02x is high for a company growing revenues at single digits, implying premium valuation versus fundamentals
- TTM sales growth of only 8% shows no meaningful acceleration despite broader healthcare sector tailwinds
- 3-year compounded profit growth of just 8% contrasts with the 25% TTM figure, raising questions about sustainability of recent profit surge
- 5-year stock CAGR of 12% is modest and trails the 3-year CAGR of 28%, indicating much of the re-rating is recent and potentially fragile
- Dividend yield of 0.37% provides minimal income cushion if stock price corrects from current levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 17h ago- Record EBITDA margin at 33.6% Aug 11
FY26 PAT rose 16% YoY to ₹5,645 million on revenue of ₹25,518 million, with EBITDA margin hitting a record 33.6% driven by non-GPL business and CDMO recovery.
- Q1FY27 margins expand to 36.6% Aug 7
Q1FY27 revenue grew 6.4% YoY to ₹640 crore with net profit of ₹160 crore and EBITDA margins expanding further to 36.6%.
- Q1 net profit up 31.7% YoY Jul 30
Q1FY26 net profit surged 31.7% YoY to ₹1,600.76 million, driven by 6.4% revenue growth in the API segment.
- Final dividend of ₹5/share Aug 6
Record date fixed as September 1, 2026 for a final dividend of ₹5 per share for FY26, subject to AGM approval on September 8.
- BRSR filed with BSI assurance Aug 11
FY26 Business Responsibility & Sustainability Report submitted with 54.4% export contribution and voluntary limited assurance by British Standards Institution on core KPIs.
- Investor meets in Mumbai Aug 13
Multiple investor and analyst meetings scheduled for August 12, 18, and 19 in Mumbai, including the Emkay Confluence conference, in virtual and in-person formats.
- AGM scheduled September 8 Aug 11
15th AGM set for September 8, 2026 with agenda items including final dividend approval and re-appointment of Hiren Patel as Non-Executive Director.
- Q1 earnings call July 31 Jul 23
Q1 FY2026-27 earnings call scheduled for July 31, 2026 from 8:30 am to 9:30 am IST to discuss financial performance.
TL;DR: Alivus Life Sciences is delivering strong execution with record EBITDA margins expanding from 33.6% in FY26 to 36.6% in Q1FY27, alongside consistent double-digit profit growth. No material headwinds are visible in recent news flow. The company is actively engaging investors and rewarding shareholders with a ₹5/share dividend. The trend is clearly improving, with margin expansion and non-GPL diversification providing a positive outlook heading into FY27.
Quarterly Results
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 578 | 595 | 573 | 537 | 589 | 507 | 642 | 650 | 602 | 588 | 673 | 689 | 640 |
| Expenses | 385 | 428 | 400 | 395 | 429 | 373 | 452 | 451 | 430 | 409 | 442 | 475 | 429 |
| Operating Profit | 193 | 167 | 173 | 141 | 159 | 134 | 190 | 198 | 172 | 179 | 231 | 215 | 212 |
| OPM % | 33% | 28% | 30% | 26% | 27% | 27% | 30% | 31% | 29% | 30% | 34% | 31% | 33% |
| Other Income | 2 | 5 | 2 | 3 | 5 | 9 | 10 | 10 | 9 | 15 | -12 | 23 | 22 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 13 | 13 | 13 | 15 | 14 | 15 | 15 | 16 | 17 | 18 | 20 | 20 | 21 |
| PBT | 182 | 159 | 161 | 130 | 150 | 127 | 185 | 191 | 163 | 174 | 198 | 216 | 212 |
| Tax % | 26% | 25% | 26% | 24% | 26% | 25% | 26% | 26% | 25% | 25% | 24% | 25% | 25% |
| Net Profit | 135 | 119 | 119 | 98 | 111 | 95 | 137 | 142 | 122 | 130 | 150 | 163 | 160 |
| EPS in Rs | 11.05 | 9.69 | 9.69 | 7.99 | 9.1 | 7.78 | 11.18 | 11.58 | 9.91 | 10.6 | 12.25 | 13.25 | 13.04 |
Profit & Loss
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 886 | 1,537 | 1,885 | 2,123 | 2,161 | 2,283 | 2,387 | 2,552 | 2,590 |
| Expenses | 0 | 638 | 1,064 | 1,294 | 1,506 | 1,518 | 1,608 | 1,702 | 1,754 | 1,754 |
| Operating Profit | 0 | 248 | 473 | 592 | 617 | 643 | 675 | 684 | 798 | 837 |
| OPM % | -4% | 28% | 31% | 31% | 29% | 30% | 30% | 29% | 31% | 32% |
| Other Income | 0 | 0 | 11 | 0 | 14 | 28 | 11 | 33 | 34 | 48 |
| Interest | 0 | 1 | 34 | 88 | 28 | 1 | 2 | 2 | 5 | 5 |
| Depreciation | 0 | 19 | 29 | 33 | 38 | 42 | 53 | 61 | 75 | 79 |
| PBT | 0 | 228 | 421 | 471 | 565 | 629 | 631 | 654 | 751 | 801 |
| Tax % | 4200% | 14% | 26% | 25% | 26% | 26% | 25% | 26% | 25% | — |
| Net Profit | 0 | 196 | 313 | 352 | 419 | 467 | 471 | 486 | 564 | 603 |
| EPS in Rs | -430 | 998 | 1,597 | 359 | 34.17 | 38.11 | 38.43 | 39.63 | 45.99 | 49.14 |
| Div. Payout % | 0% | 0% | 0% | 0% | 61% | 110% | 59% | 13% | 11% | — |
Balance Sheet
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 0.01 | 2 | 2 | 2 | 25 | 25 | 25 | 25 | 25 |
| Reserves | -1 | 86 | 400 | 751 | 2,030 | 2,114 | 2,308 | 2,793 | 3,308 |
| Borrowings | 0 | 0 | 0 | 0 | 3 | 19 | 17 | 57 | 57 |
| Other Liabilities | 1 | 1,387 | 1,324 | 1,244 | 414 | 545 | 501 | 537 | 594 |
| Total Liabilities | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
| Fixed Assets | 0 | 456 | 546 | 573 | 595 | 781 | 805 | 955 | 1,038 |
| CWIP | 0 | 80 | 11 | 14 | 92 | 62 | 106 | 102 | 284 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 478 | 780 |
| Other Assets | 0 | 939 | 1,169 | 1,410 | 1,784 | 1,860 | 1,939 | 1,877 | 1,881 |
| Total Assets | 0 | 1,475 | 1,726 | 1,997 | 2,471 | 2,702 | 2,850 | 3,411 | 3,983 |
Cash Flow
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating | 0 | 10 | 195 | 388 | 598 | 306 | 414 | 392 | 565 |
| Investing | 0 | -9 | -51 | -69 | -122 | -147 | -116 | -616 | -570 |
| Financing | 0 | 1 | -137 | -214 | -79 | -388 | -279 | -6 | -64 |
| Net Cash Flow | 0 | 2 | 8 | 106 | 397 | -228 | 18 | -230 | -69 |
| Free Cash Flow | 0 | 1 | 144 | 322 | 466 | 143 | 285 | 226 | 259 |
| CFO/OP | 4,800 | 14 | 61 | 84 | 119 | 71 | 85 | 81 | 93 |
Ratios
| Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 44 | 185 | 152 | 120 | 116 | 136 | 122 | 148 | 153 |
| Inventory Days | 162 | 441 | 227 | 214 | 185 | 224 | 251 | 237 | 246 |
| Days Payable | 41 | 201 | 111 | 92 | 110 | 158 | 139 | 137 | 132 |
| Cash Conversion Cycle | 165 | 424 | 268 | 241 | 190 | 202 | 235 | 248 | 267 |
| Working Capital Days | -2,059 | -186 | -37 | 12 | 149 | 176 | 188 | 201 | 194 |
| ROCE % | — | 529% | 186% | 97% | 42% | 30% | 28% | 25% | 24% |
Documents
Frequently Asked Questions about Alivus Life Sciences Ltd
What does Alivus Life Sciences Ltd do?
Where is Alivus Life Sciences Ltd (ALIVUS) listed?
Which sector does Alivus Life Sciences Ltd belong to?
What is the market capitalisation of Alivus Life Sciences Ltd?
What is the PE ratio of Alivus Life Sciences Ltd?
What is the 52-week high and low of Alivus Life Sciences Ltd?
Does Alivus Life Sciences Ltd pay dividends?
What is the Return on Equity (ROE) of Alivus Life Sciences Ltd?
How can I research Alivus Life Sciences Ltd on Tapetide?
Company Information
Glenmark Life Sciences, a subsidiary of Nirma Limited, a diversified conglomerate with interest in consumer products, cement, chemicals and pharmaceuticals. It is a leading developer and manufacturer of select, high-value, non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The company further operates in Contract Development and manufacturing operations to offer services to specialty Pharmaceutical companies.